- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07624994
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine (CARSPECT II)
8 juli 2026 uppdaterad av: Centre Jean Perrin
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study
This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
80
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Marion CHANCHOU, Dr
- Telefonnummer: 33473278089
- E-post: marion.chachou@clermont.unicancer.fr
Studieorter
-
-
-
Clermont-Ferrand, Frankrike
- Chu Clermont Ferrand
-
Kontakt:
- SYLVAIN MATHIEU
- Telefonnummer: MD
- E-post: smathieu@chu-clermontferrand.fr
-
-
PUY DE DOME
-
Clermont-Ferrand, PUY DE DOME, Frankrike, 63011
- Centre Jean Perrin
-
Kontakt:
- MARION CHANCHOU, MD
- Telefonnummer: 04 73 27 82 01
- E-post: Marion.chanchou@clermont.unicancer.fr
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Karnofsky index > 70%
- Obtaining written, signed and dated informed consent
- Affiliation to a health insurance plan
- For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.
- Ability and willingness to respect study visits, exams as well as protocol.
RA Group:
- certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria,
- symptomatic (finger pain > 4 /10 on a numerical scale),
- active synovitis (clinical and ultrasound),
Group DOA:
- certain diagnosis of symptomatic DOA less than 5 years old (finger pain > 4 /10 on a numerical scale),
- stopping NSAIDs for at least 8 days before the injection,
Exclusion Criteria:
- Ongoing use of non-steroidal anti-inflammatory drugs,
- Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,
- History of osteoarticular hand surgery.
- History of hand soft tissue surgery in the past 6 months
- Patients or patients 18 years old,
- Pregnant or breastfeeding patient,
- IMC>30,
- History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,
- Persons deprived of their liberty, under guardianship/curatorship, or safeguarding of justice,
- Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study.
RA Group:
- Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.
- Patients with a history of hand DOA
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Rheumatoid arthritis
99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
|
1 intravenös injektion av 99mTc-NTP 15-5 vid en diagnostisk aktivitet på 15 MBq/kg (D0)
|
|
Experimentell: digital osteoarthritis
99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
|
1 intravenös injektion av 99mTc-NTP 15-5 vid en diagnostisk aktivitet på 15 MBq/kg (D0)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group: digital osteoarthritis (DOA) and rheumatoid arthritis (RA)
Tidsram: 2 hour after injection
|
The diagnostic accuracy of 99mTc-NTP 15-5 imaging in detecting an abnormal joint among the 15 joints of the hands.
The scintigraphic analysis of the joints will be visual, blinded to the pathology, and binary in nature.
A joint will be considered pathological on 99mTc-NTP 15-5 in the event of abnormal tracer uptake, compared to joints with physiological uptake.
The diagnosis of a pathological joint (gold standard) will be based on a composite radiological-clinical analysis.
|
2 hour after injection
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
to evaluate the diagnostic performance of 99mTc-NTP 15-5 for differential diagnosis between DAO and RA.
Tidsram: 2 hours after injection of 99mTc-NTP 15-5
|
Performance measures of 99mTc-NTP 15-5 imaging for distinguishing between DAO and RA. Readers will classify the scintigrams as DAO or RA based on the uptake pattern. A consensus will be sought in cases of disagreement. The gold standard will be the diagnosis determined by radioclinical analysis. |
2 hours after injection of 99mTc-NTP 15-5
|
|
to evaluate the performance of 99mTc-NTP imaging 15-5 by joint group in each pathology.
Tidsram: 2 hours after injection
|
Performance measures of 99mTc-NTP 15-5 imaging to detect an affected joint complex
|
2 hours after injection
|
|
to determine the prevalence of joint damage by pathology according to the scintigraphic method and the radioclinical method
Tidsram: 2 hours after injection
|
The proportion of joints classified as pathological, according to the scintigraphic method and the radioclinical method
|
2 hours after injection
|
|
To quantitatively analyze the fixation of 99mTc-NTP 15-5 on the hand joints, in each pathology.
Tidsram: 2 hours after injection
|
measurements of the joint/radial diaphysis ration (99mTc-NTP 15-5A/D), determined by semi-automatic contouring joint interfaces on tomoscintigraphic images and manually traced spherical region of interest on radial diaphyses.
|
2 hours after injection
|
|
to evaluate the inter-observer reproducibility of visual and quantitative readings
Tidsram: 2 hours after injection
|
Inter-observer reproducibility measures: Cohen's kappa coefficient for visual readings (before to consensus) and intra-class correlation coefficient (ICC) for quantitative readings.
|
2 hours after injection
|
|
to describe the fixation of 99mTc-NTP 15-5 on skeletal joints other than hand joints, based on visual analysis.
Tidsram: 2 hours after injection
|
All skeletal joints other than the hands will be rated by a score : 0: no fixation, 1: fixation < adjacent diaphysis, 2: fixation = adjacent diaphysis, 3: fixation > adjacent diaphysis.
|
2 hours after injection
|
|
to evaluate the tolerance of 99mTc-NTP 15-5.
Tidsram: during 1 week after injection of 99mTc-NTP 15-5
|
Adverse events (AEs) assessed according to the NCI-CTCAE V5.0 criteria and associated with 99mTc-NTP 15-5 occurring within the week following the injection.
|
during 1 week after injection of 99mTc-NTP 15-5
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Marion CHANCHOU, Dr, Centre Jean Perrin
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 augusti 2026
Primärt slutförande (Beräknad)
1 juli 2028
Avslutad studie (Beräknad)
1 juli 2028
Studieregistreringsdatum
Först inskickad
29 maj 2026
Först inskickad som uppfyllde QC-kriterierna
29 maj 2026
Första postat (Faktisk)
3 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
10 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
8 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2025-523650-14-00
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
OBESLUTSAM
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .